Zai Lab Limited Unsponsored ADR (ZLAB) - What Are Brokerages Thinking About This Stock?

Key Points

• Analysts have a “Moderate Buy” consensus on Zai Lab, with four buy ratings, one strong buy, one hold and one sell. The average 12-month price target is $37.25, above the reported share price of $23.19.
• Zai Lab reported a quarterly loss of $0.50 per share on $106.31 million in revenue, while analysts expect a full-year loss of $2.37 per share. The company also posted negative net margin and return on equity.
• Institutional investors own 41.65% of the stock, with several funds increasing their positions, while insiders sold approximately $235,000 worth of shares over the past 90 days.

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $37.25.

ZLAB has been the subject of several analyst reports. Wall Street Zen upgraded Zai Lab from a "sell" rating to a "hold" rating in a report on Saturday, September 26th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zai Lab in a research note on Tuesday, October 6th. Citigroup lifted their price target on Zai Lab from $44.00 to $45.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Weiss Ratings upgraded Zai Lab from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, July 29th. Finally, Zacks Research raised shares of Zai Lab from a "strong sell" rating to a "hold" rating in a research report on Tuesday, July 7th.

Zai Lab Stock Performance

NASDAQ:ZLAB opened at $23.19 on Friday. Zai Lab has a one year low of $15.96 and a one year high of $29.77. The stock has a market cap of $2.64 billion, a PE ratio of -13.56 and a beta of 0.73. The stock has a 50 day moving average price of $25.39 and a 200 day moving average price of $21.63.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.50) EPS for the quarter. The company had revenue of $106.31 million for the quarter. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%. As a group, analysts predict that Zai Lab will post -2.37 earnings per share for the current fiscal year.

Insider Activity

In related news, Director William Lis sold 8,506 shares of the firm's stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total transaction of $212,650.00. Following the completion of the sale, the director directly owned 41,931 shares in the company, valued at approximately $1,048,275. This trade represents a 16.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 9,385 shares of company stock valued at $235,145 over the last ninety days. Corporate insiders own 4.88% of the company's stock.

Hedge Funds Weigh In On Zai Lab

Institutional investors have recently bought and sold shares of the company. Seven Fleet Capital Management LP boosted its holdings in Zai Lab by 74.7% in the 2nd quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company's stock valued at $2,584,000 after purchasing an additional 58,158 shares during the last quarter. Headlands Technologies LLC increased its holdings in shares of Zai Lab by 142.0% during the 2nd quarter. Headlands Technologies LLC now owns 68,010 shares of the company's stock worth $1,292,000 after buying an additional 39,901 shares during the last quarter. WealthPlan Investment Management LLC acquired a new stake in shares of Zai Lab during the 3rd quarter worth approximately $969,000. Finally, Nykredit A S acquired a new stake in shares of Zai Lab during the 2nd quarter worth approximately $79,000. 41.65% of the stock is owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Ltd. NASDAQ: ZLAB is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases with significant unmet medical needs. The company's research and development activities span oncology, autoimmune and inflammatory disorders, infectious diseases, and neuroscience.

Founded in 2014 by Samantha Du, Zai Lab has built a portfolio through internal research as well as licensing and collaboration agreements with international pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.